We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
An employer can suspend an employee from work if their health and safety is in danger - employee right to pay, alternative work and how to handle problems
This PAR covers the assessment of an application to reclassify Allevia 120mg tablets from Prescription Only Medicine (POM) to General Sales List (GSL).
Resources to help schools plan and provide healthy food in schools.
Government wants to see improved clarity and consistency in how the sector deals with allergies.
The government has launched a consultation to strengthen allergen labelling laws.
‘Natasha’s Law’ introduced to protect allergy sufferers and give them confidence in the food they buy.
This document contains the following information: Government response to the House of Lords Science and Technology Committee report on allergy - 6th report of session 2006-07.
First published during the 2005 to 2010 Labour government
Details of the Yellow Card scheme, which is the system for recording adverse incidents with medicines and medical devices in the UK.
The Government Chemist contributed to updating an Information Statement on Food Allergy for the Institute of Food Science & Technology, IFST.
Find out the information you must give to customers on food products and how to give it.
Surgeons reminded to have competent personnel and emergency facilities available for at least 1 hour after administration of the blue dye.
The MHRA has reviewed the latest evidence relating to the very rare risk of PRES and RCVS associated with medicines containing pseudoephedrine
There have been very rare reports of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) with pseudoephedrine.
Second webinar in the Quarterly Webinar Series of the Joint Knowledge Transfer Framework for Food Standards and Food Safety Analysis on 16 June
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.